Canada markets open in 5 hours 20 minutes

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.39+0.24 (+0.92%)
At close: 04:00PM EST
26.45 +0.06 (+0.23%)
After hours: 07:50PM EST

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760 931 9200
https://www.ionispharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees757

Key Executives

NameTitlePayExercisedYear Born
Dr. Brett P. Monia Ph.D.Founder, CEO & Director1.34M2.3M1961
Ms. Elizabeth L. HougenExec. VP & CFO862.13k2.26M1962
Mr. Patrick R. O'Neil Esq.Exec. VP, Chief Legal Officer & Gen. Counsel822.93kN/A1974
Dr. Stanley T. CrookeScientific Advisor1.31M327.85k1945
Ms. B. Lynne ParshallSr. Strategic Advisor & Director1.03M376.15k1954
Dr. Richard S. GearyExec. VP & Chief Devel. Officer868.91k1.25M1958
Mr. Joel EdwardsVP of Corp. OperationsN/AN/A1961
Mr. Darren GonzalesChief Accounting Officer & Sr. VPN/AN/AN/A
Dr. C. Frank BennettExec. VP & Chief Scientific OfficerN/AN/A1957
Mr. David NakasoneInvestor Relations OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.